Takeda Pharmaceutical (TAK) Cash from Investing Activities (2018 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Cash from Investing Activities of -$550.2 million for Q2 2026, down 139.86% year-over-year from $1.4 billion in Q2 2025, and down 48.73% quarter-over-quarter from -$369.9 million in Q1 2026.
Takeda Pharmaceutical (TAK) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$550.2 million for Q2 2026.
- In Q2 2026, Cash from Investing Activities fell 139.86% year-over-year to -$550.2 million; the TTM figure through Jun 2026 stood at -$2.7 billion (down 68.91% YoY), while the FY2026 annual figure was -$2.5 billion, down 1.77% from the prior year.
- Cash from Investing Activities for Q2 2026 stood at -$550.2 million, down from -$369.9 million in the prior quarter.
- The five-year high for Cash from Investing Activities was -$129.0 million in Q1 2025, with the low at -$3.3 billion in Q1 2023.
- The 5-year median for Cash from Investing Activities is -$461.6 million (2024), against an average of -$747.4 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities slumped 1402.64% in 2023, then surged 87.48% in 2024.
- Takeda Pharmaceutical's Cash from Investing Activities stood at -$330.5 million in 2022, then plunged by 54.08% to -$509.2 million in 2023, then slumped by 49.27% to -$760.1 million in 2024, then plunged by 96.45% to -$1.5 billion in 2025, then soared by 63.15% to -$550.2 million in 2026.
- Business Quant data shows TAK's Cash from Investing Activities at -$550.2 million in Q2 2026, -$369.9 million in Q1 2026, and -$1.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | -2.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -550.24 Mn |
| Jun 30, 2026 | -550.24 Mn |
| Mar 31, 2026 | -369.95 Mn |
| Mar 31, 2026 | -369.95 Mn |
| Dec 31, 2025 | -1.49 Bn |
| Dec 31, 2025 | -1.49 Bn |
| Sep 30, 2025 | -326.67 Mn |
| Sep 30, 2025 | -326.67 Mn |
| Jun 30, 2025 | -229.40 Mn |
| Jun 30, 2025 | -229.40 Mn |
| Mar 31, 2025 | -129.00 Mn |
| Mar 31, 2025 | -129.00 Mn |
| Dec 31, 2024 | -760.09 Mn |
| Dec 31, 2024 | -760.09 Mn |
| Sep 30, 2024 | -503.69 Mn |
| Sep 30, 2024 | -503.69 Mn |
| Jun 30, 2024 | -1.01 Bn |
| Jun 30, 2024 | -1.01 Bn |
| Mar 31, 2024 | -414.88 Mn |
| Mar 31, 2024 | -414.88 Mn |